Natural product-based anti-ageing and Lifespan extension therapy:  A pharmaceutical mixture encompassing Celecoxib and quercetin (CQ) increases CHIP levels, increases monoubiquitylation of insulin receptor (INSR), decreases INSR protein levels and enhances lifespan, via down regulation of its target gene, 15/January/2019, 11.47 pm

Molecular therapy for glaucoma: Ulinastatin (trade name: Miraclid, Ulinase, U-Tryp,Bikunin and Urinastatin), an urinary trypsin inhibitor used in the treatment of  acute/chronic pancreatitis, burns and others,  increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 15/January/2018, 11.36 pm
January 15, 2019
RNA-based therapy for aging-associated diseases and Lifespan extension: LncRNA PRLB  inhibits the interaction of DBC1 with PARP1, increases the PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer and aging, via down-regulation of its target gene, 15/January/2019, 11.58 pm
January 15, 2019
Show all

Introduction: What they say 

A study from Institute for Cell Biology, University of Bonn, Ulrich-Haberland Str.  Bonn, Germany; and Institute for Genetics and CECAD Research Center, University of Cologne, Joseph-Stelzmann Str. Cologne, Germany shows that “The Ubiquitin Ligase CHIP Integrates Proteostasis and Aging by Regulation of Insulin Receptor Turnover.” This research paper was published, in the 20 April 2017 issue of the journal “Cell” [One of the best research journals in Biology with an I.F of 28 plus], by Prof. Hoppe T,Tawo R and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Natural product-based anti-ageing and Lifespan extension therapy:  A pharmaceutical mixture encompassing Celecoxib and quercetin (CQ) increases CHIP levels, increases monoubiquitylation of insulin receptor (INSR), decreases INSR protein levels and enhances lifespan, via down regulation of its target gene


What is known?

Prof. Hoppe T’s research team has recently shown that knocking down CHIP gene in mice results in a) increased protein levels of insulin receptor (INSR); and b) reduced lifespan. Further, they have shown that CHIP targets INSR for mono ubiquitylation and degradation, while its ability to degrade INSR is compromised upon proteotoxic stress and during ageing, as CHIP is directed toward disposal of misfolded proteins rather than degrade the INSR.


From Research findings to Therapeutic opportunity:

This study suggests a natural product-based anti-ageing therapy. A pharmaceutical mixture encompassing celecoxib and quercetin (CQ), by decreasing the expression of its target gene, it may increase the levels of CHIP (carboxy terminus of Hsc70 interacting protein). Thereby, it may: (1) increase CHIP-assisted proteolysis; (2) increase mono ubiquitylation and degradation of INSR; (3) inhibit the insulin and IGF1 signaling pathway; and (4) enhance longevity (Fig1).

Figure 1. Mechanistic insights into how a pharmaceutical mixture encompassing celecoxib and quercetin (CQ) induces CHIP expression and extends lifespan

Figure 2. The chemical structure of  celecoxib and quercetin (CQ).

Thus, pharmacological formulations encompassingcelecoxib and quercetin (CQ) or their analogues, either alone or in combination with compounds,may be used to suppress age-associated overall physiological decline and improve health/life span.

[easy_payment currency=”USD”]


Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How a pharmaceutical mixture encompassing celecoxib and quercetin (CQ) decreases the levels of INSR and promotes longevity

Amount:$300#

# Research cooperation


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., Natural product-based anti-ageing and Lifespan extension therapy: A pharmaceutical mixture encompassing Celecoxib and quercetin (CQ) increases CHIP levels, increases monoubiquitylation of insulin receptor (INSR), decreases INSR protein levels and enhances lifespan, via down regulation of its target gene, 15/January/2019, 11.47 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite us, kindly drop us a line at info@genomediscovery.org

Comments are closed.